Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Sisram Medical Ltd (1696.HK)
Caesarea, IL
Sisram Medical Ltd, an investment holding company headquartered in Caesarea, Israel, since its establishment in 2013, is engaged in the creation, production, and worldwide distribution of a broad spectrum of medical solutions. The company develops and markets energy-based aesthetic devices, minimally invasive therapeutic systems, non-energy-dependent equipment, and cosmeceuticals, reaching markets across Asia Pacific, Europe, North America, Latin America, the Middle East, and Africa. Its comprehensive range of products and treatments addresses numerous conditions, such as hair removal, skin revitalization, acne and scarring, body and facial sculpting, pigment and skin surface refinement, fat transfer procedures, injectable dermal fillers, skin tissue regeneration injectables, personal wellness items, cosmetic dental procedures, transdermal delivery methods, cellulite reduction, stretch mark amelioration, therapy for vascular and pigmented lesions, hydradermabrasion, non-surgical eyelid lifts (blepharoplasty), liposuction, as well as feminine health and sexual well-being applications. Furthermore, the company is involved in the manufacturing, distribution, and sales of general medical apparatus. Sisram Medical's offerings are available under its prominent brand names, which include Alma, Soprano, Harmony, Copulla, Foshion, Accent, and LMNT.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.09% | -7.19% | -7.19% | -33.25% | -33.74% | -35.63% | -40.57% | -70.99% | -86.97% | -66.63% | -66.63% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | -1 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%+4.7% Q4'25: +6.5% (vs Q4'23)
-
EPS growth Medical - Devices: +28.5%-24.3% Q4'25: -0.4% (vs Q4'23)
-
FCF margin FCF growth · Medical - Devices: +30.9%-0.3% Q4'25: +6.9% (vs Q4'23)
-
EBIT margin Medical - Devices: +6.2%+7.4% ★ Q4'25: +9.2% (vs Q4'23)
-
ROIC Medical - Devices: +3.3%+4.9% ★ Q4'25: +14.5% (vs Q4'23)
-
Share dilution Medical - Devices: 0.0%+0.0% ★ Q4'25: +0.2% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×1.35× ★ Q4'25: 0.54× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 1 EPS Ana. |
Dec 2027 2 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
136.89M
est: 132.01M (+3.7%)
|
153.92M
est: 149.02M (+3.3%)
|
173.52M
est: 169.31M (+2.5%)
|
294.29M
est: 216.83M (+35.7%)
|
354.48M
est: 361.75M (-2.0%)
|
359.29M
est: 45.65M (+687.1%)
|
349.11M
est: 369.06M (-5.4%)
|
365.35M
est: 373.34M (-2.1%)
|
411.53M
404.03M – 419.03M
+10.2% YoY
|
459.49M
443.61M – 475.37M
+11.7% YoY
|
516.31M
502.43M – 530.18M
+12.4% YoY
|
| EBITDA |
27.02M
est: 20.83M (+29.7%)
|
29.55M
est: 23.51M (+25.7%)
|
35.29M
est: 26.71M (+32.1%)
|
55.96M
est: 34.21M (+63.6%)
|
58.38M
est: 57.08M (+2.3%)
|
53.43M
est: 6.57M (+713.3%)
|
38.91M
est: 53.12M (-26.7%)
|
38.22M
est: 53.73M (-28.9%)
|
59.23M
58.15M – 60.31M
+10.2% YoY
|
66.13M
63.85M – 68.42M
+11.7% YoY
|
74.31M
72.31M – 76.31M
+12.4% YoY
|
| EBIT |
21.15M
est: 15.20M (+39.1%)
|
23.73M
est: 17.16M (+38.3%)
|
25.57M
est: 19.50M (+31.1%)
|
43.68M
est: 24.97M (+74.9%)
|
45.98M
est: 41.66M (+10.4%)
|
39.19M
est: 4.93M (+694.3%)
|
27.68M
est: 39.89M (-30.6%)
|
27.03M
est: 40.36M (-33.0%)
|
44.48M
43.67M – 45.29M
+10.2% YoY
|
49.67M
47.95M – 51.38M
+11.7% YoY
|
55.81M
54.31M – 57.31M
+12.4% YoY
|
| Net Income |
11.05M
est: 23.43M (-52.8%)
|
21.83M
est: 32.74M (-33.3%)
|
20.79M
est: 37.42M (-44.5%)
|
31.25M
|
40.17M
est: 38.45M (+4.5%)
|
31.50M
est: 23.57M (+33.6%)
|
25.13M
est: 28.14M (-10.7%)
|
19.02M
est: 40.31M (-52.8%)
|
28.86M
23.27M – 34.44M
-28.4% YoY
|
34.54M
28.78M – 40.29M
+19.7% YoY
|
45.24M
43.66M – 46.82M
+31.0% YoY
|
| SGA |
39.92M
est: 52.43M (-23.9%)
|
47.44M
est: 59.18M (-19.9%)
|
59.33M
est: 67.24M (-11.8%)
|
100.71M
est: 86.12M (+16.9%)
|
128.76M
est: 143.67M (-10.4%)
|
159.44M
est: 18.95M (+741.4%)
|
165.09M
est: 153.21M (+7.8%)
|
165.73M
est: 154.99M (+6.9%)
|
170.84M
167.73M – 173.96M
+10.2% YoY
|
190.75M
184.16M – 197.34M
+11.7% YoY
|
214.34M
208.58M – 220.10M
+12.4% YoY
|
| EPS |
0.04
est: 0.05 (-22.4%)
|
0.05
est: 0.07 (-29.3%)
|
0.05
est: 0.08 (-41.2%)
|
0.07
|
0.09
est: 0.08 (+2.2%)
|
0.07
est: 0.05 (+33.7%)
|
0.05
est: 0.06 (-10.8%)
|
0.04
est: 0.09 (-52.8%)
|
0.06
0.05 – 0.07
-28.4% YoY
|
0.07
0.06 – 0.09
+19.7% YoY
|
0.10
0.09 – 0.10
+31.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 2/5 | 5/5 |
| 2026-05-28 | A | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 2/5 | 5/5 |
| 2026-05-27 | A | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 2/5 | 5/5 |
| 2026-05-26 | A | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 2/5 | 5/5 |
| 2026-05-22 | A | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 2/5 | 5/5 |
| 2026-05-21 | A | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 2/5 | 5/5 |
| 2026-05-20 | A | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 2/5 | 5/5 |
| 2026-05-19 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-18 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-15 | A | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 3/5 | 5/5 |
| 2026-05-14 | A | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 3/5 | 5/5 |
| 2026-05-13 | A | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 3/5 | 5/5 |
| 2026-05-12 | A | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 3/5 | 5/5 |
| 2026-05-11 | A | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 3/5 | 5/5 |
| 2026-05-08 | A | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 3/5 | 5/5 |
| 2026-05-07 | A | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 3/5 | 5/5 |
| 2026-05-06 | A | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 3/5 | 5/5 |
| 2026-05-05 | A | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 3/5 | 5/5 |
| 2026-05-04 | A | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 3/5 | 5/5 |
| 2026-04-30 | A- | 4/5 | 4/5 | 2/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-29 | A- | 4/5 | 4/5 | 2/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-28 | A- | 4/5 | 4/5 | 2/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-27 | A- | 4/5 | 4/5 | 2/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-24 | A- | 4/5 | 4/5 | 2/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-23 | A- | 4/5 | 4/5 | 2/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-22 | A- | 4/5 | 4/5 | 2/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-21 | A- | 4/5 | 4/5 | 2/5 | 5/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-20 | A- | 4/5 | 4/5 | 2/5 | 5/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-17 | A- | 4/5 | 4/5 | 2/5 | 5/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-16 | A- | 4/5 | 4/5 | 2/5 | 5/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-15 | A- | 4/5 | 4/5 | 2/5 | 5/5 | 2/5 | 3/5 | 5/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | WisdomTree International SmallCap Dividend Fund DLS | 0.03% | 267.0K | 0.58% |
| 2 | WisdomTree Dynamic International SmallCap Equity ETF DDLS | 0.03% | 109.2K | 0.48% |
| 3 | WisdomTree International Equity Fund DWM | 0.01% | 56.5K | 0.48% |
| 4 | Avantis International Small Cap Value ETF AVDV | 0.00% | 5.8K | 0.36% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Lior Moshe Dayan | Executive Chairman & President | 11M | male |
| Jiahong Li | Co-CEO, CFO & Executive Director | 3M | male |
| Itay Meir | EVP of R&D | — | male |
| Keith Adams | Senior VP of Corporate Development & Chairman of Alma Inc. | — | male |
| Nikol Lev | Chief Information Officer | — | female |
| Orit Segal | Chief People Officer | — | female |
| Qianli Fang | Company Secretary | — | female |
| Ran Ezioni | Chief Operating Officer | — | male |
| Eyal Ben David | Co-Chief Executive Officer | — | male |
| Tal Burgan Rosen | Chief Marketing Officer | — | female |
| Hui Fan | Investor Relations Director | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 1696.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
